Clik here to view.
RoslinCT、ピーター・マティソン教授とアレクサンダー・ヴォス氏を新たに非業務執行取締役に任命
スコットランド、エディンバラ＆ボストン （ビジネスワイヤ） — 細胞・遺伝子治療開発製造受託機関（CDMO）の優良企業であるRoslinCTは、ピーター・マティソン教授（名誉MB BS、PhD、FRCP、FRCPE、FMedSci、FRSE、FRSA）とアレクサンダー・ヴォス氏を新たに非業務執行取締役に任命したことをお知らせいたします。...
View ArticleClik here to view.
RoslinCT任命Peter Mathieson爵士教授和Alexander Vos为新的非执行董事
苏格兰爱丁堡和波士顿 (美国商业资讯)– 领先的细胞和基因治疗合同开发和制造组织(CDMO) RoslinCT欣然宣布，任命Peter Mathieson MB BS (Hons), PhD, FRCP, FRCPE, FMedSci, FRSE, FRSA爵士教授和Alexander Vos为新的非执行董事。 Peter...
View ArticleClik here to view.
Takeda Announces New Assignments of Directors
OSAKA, Japan Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the...
View ArticleClik here to view.
武田薬品工業: 取締役分掌等の決定について
大阪 （ビジネスワイヤ） — 当社は本日、大阪市内で開催した第148回定時株主総会後の取締役会および監査等委員会において、取締役分掌等を下記のとおり決定しましたのでお知らせします。...
View ArticleClik here to view.
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step...
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), a global pharmaceutical...
View ArticleClik here to view.
Takeda宣布新的董事任命
日本大阪 (美国商业资讯)– Takeda (TOKYO:4502/NYSE:TAK)于今日在大阪举行了第148届股东常会，并在随后的董事会会议和审计与监督委员会会议上宣布了新的董事任命。 Takeda董事会共有14名成员，其中有11名成员担任外部董事，这有助于确保透明、公正。一名外部董事将继续担任董事会主席。审计与监督委员会、提名委员会和薪酬委员会将完全由外部董事组成，包括其主席在内。...
View ArticleClik here to view.
Clik here to view.
QPS宣布为临床试验和细胞疗法开发提供新的实验室服务
德克萨斯州纽瓦克 (美国商业资讯)– 全球领先的合同研究组织（CRO）QPS欣然宣布推出新的实验室服务能力。中心实验室、Leukopak细胞治疗设施和增强型PBMC能力将补充现有的生物分析、转化医学和外周血单核细胞 (PMBC) 实验室，并扩展QPS目前提供的全方位全球CRO服务。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
ReCerise Therapeutics Inc. Selected for Government Project by MOTIE
SEOUL, South Korea ReCerise Therapeutics Inc. (CEO Yong-Bae Kim), has announced its selection for a grant from the Ministry of Trade, Industry and Energy (MOTIE) of South Korea. The grant aims to...
View ArticleClik here to view.
Signet Therapeutics Announces IND Approval by the FDA for World’s First...
BOSTON Signet Therapeutics, a biotech company using organoid disease models and AI to advance targeted cancer therapy, today announced that the FDA has granted its IND application for sigx1094 as a...
View ArticleClik here to view.
Dongguk University Ilsan Hospital Completes First Brain Tumor Treatments with...
GOYANG-SI, South Korea ZAP Surgical Systems, Inc., a global leader in surgical robotics, proudly announces the completion of first patient treatments at Dongguk University Ilsan Hospital using the...
View ArticleClik here to view.
Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase...
TOKUSHIMA, Japan We are excited to share our latest development status. We are pleased to announce that the enrollment of patients in the Phase III clinical trial of DFP-14323 in combination with...
View ArticleClik here to view.
Delta-Fly Pharma Inc.：关于启动DFP-14323 III期关键性比较临床试验患者招募的通知
日本德岛 (美国商业资讯)– 我们很高兴与大家分享我们最新的研发进展。 我们欣然宣布，DFP-14323联合阿法替尼（20 mg/天）对比单独使用阿法替尼（40 mg/天）治疗携带罕见表皮生长因子受体(EGFR)阳性突变的III/IV期非小细胞肺癌患者的III期临床试验的患者招募已于即日起在日本开始。该临床实验已于2024年2月经日本药品和医疗器械管理局(PMDA)批准。...
View ArticleClik here to view.
Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug...
SEOUL, South Korea Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of...
View ArticleClik here to view.
PharmaEssentia Promotes Robert B. Geller, M.D. to General Manager
BURLINGTON, Mass. PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven...
View ArticleClik here to view.
Taiho Pharmaceutical Exercises Option for an Exclusive License to...
HAYWARD, Calif. & TOKYO Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International...
View ArticleClik here to view.
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent...
SHANGHAI, China & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the second quarter of 2024 and recent corporate updates,...
View ArticleClik here to view.
Sensome Signs Exclusive Commercial Distribution Agreement for Clot-Sensing...
PARIS Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced an exclusive distribution agreement (the “Agreement”) in Japan with Cosmotec, an M3...
View ArticleClik here to view.
Sunbird Bio to Present Data from Study Evaluating Tau Blood-Based Biomarkers...
CAMBRIDGE, Mass. & SINGAPORE Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage...
View ArticleClik here to view.
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS...
BOSTON Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the first patient has been dosed in a Phase...
View Article